Nazish Ahmad, MD
Endocrinology, Diabetes & Metabolism · Pennington, NJNPI 1295098903
Payments from drug & device makers
Across 28 payments — averaging $24.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$228
- Bristol Myers Squibb$60
- Medtronic$59
- GSK$38
- AstraZeneca$36
- Progenics Pharmaceuticals, Inc.$35
- plus $233 from 12 others
What the payments were for
- Food & beverage$67498%
- Education$142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 3 | $228 |
| Bristol Myers Squibb | 3 | $60 |
| Medtronic(2 entities) | 3 | $59 |
| GSK | 2 | $38 |
| AstraZeneca(2 entities) | 2 | $36 |
| Progenics Pharmaceuticals, Inc. | 2 | $35 |
| RGH Enterprises LLC | 1 | $33 |
| Novo Nordisk | 2 | $30 |
| Dexcom, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Merck | 1 | $17 |
| Novartis | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$177
How this compares
$688 in reported general payments places this provider in the 30th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 360 | $549,153 |
| MounjaroTirzepatide | 259 | $460,482 |
| JardianceEmpagliflozin | 129 | $162,753 |
| TrulicityDulaglutide | 91 | $121,506 |
| JanuviaSitagliptin Phosphate | 78 | $83,895 |
| Tresiba Flextouch U-100Insulin Degludec | 101 | $76,978 |
| FarxigaDapagliflozin Propanediol | 54 | $62,569 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $43,841 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $35,650 |
| Bydureon BciseExenatide Microspheres | 25 | $33,825 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 187 | $29,107 |
| TradjentaLinagliptin | 35 | $27,697 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $26,580 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $24,415 |
| Humalog Kwikpen U-100Insulin Lispro | 89 | $21,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $30 | $552,739383 claims |
| MerckJanuvia, Janumet | $17 | $89,79589 claims |
| AstraZenecaFarxiga | $36 | $62,56954 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Pennington
- Taher ModarressiPennington$414K
- Sudeep DhillonPennington$45K
- Yan WuPennington$13K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.